Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02661464 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
A Phase 3 study, sponsored by Janssen Vaccines & Prevention B.V..
- Terminated
- Registry status
- Phase 3
- Development phase
- 677
- Enrollment target
NCT02661464 is a Phase 3 study that was terminated before completion, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 677 participants.
The verdict
NCT02661464, a Phase 3 study, was terminated before completion, sponsored by Janssen Vaccines & Prevention B.V..
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 677 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the long-term safety profile of Ad26.ZEBOV and MVA-BN-Filo in participants previously exposed to these vaccines in Phase 1, 2, or 3 clinical studies.
Interventions
- BIOLOGICAL Ad26.ZEBOV
- BIOLOGICAL MVA-BN-Filo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 677 participants |
| Start Date | 2016-05-31 |
| Est. Completion | 2021-12-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02661464
The ClinicalTrials.gov registry entry for NCT02661464 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 677 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Vaccines & Prevention B.V., which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ad26.ZEBOV is the first listed.
NCT02661464 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02661464 about?
NCT02661464 is a clinical study titled "Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo". The purpose of the study is to assess the long-term safety profile of Ad26.ZEBOV and MVA-BN-Filo in participants previously exposed to these vaccines in Phase 1, 2, or 3 clinical studies.
What is the current status of trial NCT02661464?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 677 participants. The study started on 2016-05-31. Estimated completion is 2021-12-13.
What interventions are being tested in trial NCT02661464?
The interventions under investigation include: Ad26.ZEBOV (BIOLOGICAL), MVA-BN-Filo (BIOLOGICAL).
Who is sponsoring clinical trial NCT02661464?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.